Avalo Therapeutics (AVTX) Reiterated at Overweight by Cantor Fitzgerald

September 16, 2026 7:39 AM EDT Send to a Friend
Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Avalo Therapeutics Inc. (NASDAQ: AVTX).The analyst commented, "IL-1 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login